DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: ABT-126

First Posted Date: 2012-09-05

Last Posted Date: 2021-07-07

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 157

Registration Number: NCT01678755

Locations: 🇺🇸
Site Reference ID/Investigator# 73984, Lake Charles, Louisiana, United States
🇺🇸
Site Reference ID/Investigator# 72702, DeSoto, Texas, United States
🇺🇸
Site Reference ID/Investigator# 72704, Garden Grove, California, United States

and more 17 locations

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: ABT-126

First Posted Date: 2012-08-31

Last Posted Date: 2021-08-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 349

Registration Number: NCT01676935

Locations: 🇷🇺
Site Reference ID/Investigator# 73519, Moscow, Russian Federation
🇵🇱
Site Reference ID/Investigator# 73514, Poznan, Poland
🇵🇱
Site Reference ID/Investigator# 73515, Szczecin, Poland

and more 26 locations

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C

Phase 3

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ABT-450/r/ABT-267, ABT-333
Drug: Ribavirin

First Posted Date: 2012-08-29

Last Posted Date: 2021-07-12

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 187

Registration Number: NCT01674725

A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection

Phase 2

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ABT-450/ritonavir, ABT-267

First Posted Date: 2012-08-27

Last Posted Date: 2018-05-30

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 110

Registration Number: NCT01672983

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee

Phase 1

Completed

Conditions: Osteoarthritis

Interventions: Biological: ABT-981
Biological: Placebo

First Posted Date: 2012-08-20

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 36

Registration Number: NCT01668511

Locations: 🇺🇸
Site Reference ID/Investigator# 78613, Miami, Florida, United States

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Completed

Conditions: Human Immunodeficiency Virus Infection

Interventions: Drug: Lopinavir / ritonavir
Behavioral: Kaletra Adherence Support Assistance Program

First Posted Date: 2012-08-10

Last Posted Date: 2018-01-29

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 173

Registration Number: NCT01662336

Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Brain Metastases From Non-small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Veliparib
Radiation: Whole brain radiation therapy

First Posted Date: 2012-08-06

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 307

Registration Number: NCT01657799

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: ABT-126
Drug: Placebo

First Posted Date: 2012-08-02

Last Posted Date: 2021-07-07

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 432

Registration Number: NCT01655680

Locations: 🇺🇸
Site Reference ID/Investigator# 75136, New Haven, Connecticut, United States
🇷🇺
Site Reference ID/Investigator# 94476, Chita, Russian Federation
🇷🇺
Site Reference ID/Investigator# 81934, Moscow, Russian Federation

and more 58 locations

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Terminated

Conditions: Fibrosing Colonopathy

Interventions: Biological: ULTRESA
Biological: PANCREAZE
Biological: CREON
Biological: ZENPEP
Biological: other non-sponsor pancreatic enzyme replacement therapy
Biological: PERTZYE
Other: No pancreatic enzyme replacement therapy

First Posted Date: 2012-07-27

Last Posted Date: 2021-03-22

Lead Sponsor: AbbVie

Target Recruit Count: 17

Registration Number: NCT01652157

Locations: 🇺🇸
Alaska Medical Center /ID# 79256, Anchorage, Alaska, United States
🇺🇸
Arkansas Children's Hospital /ID# 79265, Little Rock, Arkansas, United States
🇺🇸
University of Arizona Cancer Center - North Campus /ID# 78939, Tucson, Arizona, United States

and more 120 locations

Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Biological: Adalimumab
Biological: placebo

First Posted Date: 2012-07-20

Last Posted Date: 2015-01-19

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 425

Registration Number: NCT01646073

Locations: 🇨🇳
Site Reference ID/Investigator# 72976, Chongqing, China
🇨🇳
Site Reference ID/Investigator# 72880, Dalian, China
🇨🇳
Site Reference ID/Investigator# 72974, Guangzhou, China

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy